about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsCognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisSerotonergic regulation of excitability of principal cells of the dorsal cochlear nucleus.Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration.Serotonin impairment in CSF of PD patients, without an apparent clinical counterpartSide effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.Monoamine reuptake inhibitors in Parkinson's disease.In Vivo Evaluation of Blood Based and Reference Tissue Based PET Quantifications of [11C]DASB in the Canine Brain.Behavioral impairments and serotonin reductions in rats after chronic L-dopa.Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.Olfaction in Parkinson's disease and related disorders.Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant α-synuclein.Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.Presynaptic serotonergic gating of the subthalamonigral glutamatergic projection.Microfluidic systems for studying neurotransmitters and neurotransmissionSerotonin2C Receptors and the Motor Control of Oral ActivityTreatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease.Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.Fatigue and Muscle Strength Involving Walking Speed in Parkinson's Disease: Insights for Developing Rehabilitation Strategy for PD.The serotonergic system in motor and non-motor manifestations of Parkinson's disease.The pathomechanisms underlying Parkinson's disease.Reduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.Non-human primate models of PD to test novel therapies.Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.5-HT2A Receptor Binding in the Frontal Cortex of Parkinson's Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study.Serotonergic Modulation of Sensory Representation in a Central Multisensory Circuit Is Pathway Specific.8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats.Serotonergic system in hypoxic ventilatory response in unilateral rat model of Parkinson's disease.L-Dopa and Brain Serotonin System Dysfunction.Obstructive sleep apnea and neurodegenerative diseases: A bidirectional relation.Effects of simvastatin on the expression of inducible nitric oxide synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of Parkinson disease.PET Imaging of Serotonin Transporters With 4-[(18)F]-ADAM in a Parkinsonian Rat Model With Porcine Neural Xenografts.Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease.Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
P2860
Q21129423-930BDD73-6608-419D-841B-CD17A9A46931Q28073680-E4BBF1AB-7300-471B-B667-89252A1A325BQ28384572-77BDE3D3-CFCC-4C9F-8D2E-D486D3F3553AQ30402720-9D4BB293-6D45-47E8-BEB5-333B136520DBQ30575965-23827DA6-EE5B-4C6F-B382-C0952F9011EAQ33921178-0E5100C0-0BAF-46DD-8F57-9C4D024C4995Q34795714-0524C305-21C2-44C1-9472-F8EB3679387CQ35165280-1A64BDB2-100B-4F16-B078-A502ADD048C5Q35918437-5B13ADB1-E69F-475D-BB9E-F985944CB639Q35952007-F21F3FB3-0F10-4471-8D62-52DC9EF5E770Q36020776-2C0DA5D5-797F-4FE3-AE27-A36BF3630872Q36193915-C22C7586-B6CC-4494-9BAC-4E86C795017AQ36400251-48925C5B-99E6-4842-918E-2072064183D6Q36680671-2120A6E2-F992-4886-995E-5004CCB8C23BQ36743112-98E98C5B-8CA0-4ADE-832A-BFCA6697228BQ36784338-AEC68822-8CCA-47F1-BD56-72DE84746D79Q36798864-77FC22D2-892C-4C3B-8463-E32082DDCB75Q37506507-8633044A-7828-4E29-9603-6566F03E4843Q37635829-E172940C-E509-4920-A7E4-11B839105610Q37644437-7B9AA4FC-7DA0-4D0E-B985-A375D90ABC23Q37685721-F3F47E62-47EA-42D0-8097-512518E7BCFAQ38118061-91ED137E-E9D8-4910-A6E4-653A35DC45A5Q38182660-E84FF144-C7CD-4F14-897D-F3FE317FF7E0Q38314696-87EF81BF-5CFE-48A5-A713-8B082CBD5492Q38658203-9430275E-3C03-4077-B166-FD476C778F11Q38845546-E76C7417-318F-4C94-9B33-22FEB29E3EFDQ39125374-008E086C-8B1D-4A4D-AD44-A4EA98212084Q39229450-D9941725-445F-4BB3-97B8-5D9FDB0F14F1Q40790760-CE2015F7-1E6E-4BAA-8BD6-6FBBF068D0A8Q41694670-4E3C1F78-1523-4B3E-9957-7EDE328E32EBQ41729961-A89AF57B-5D60-4215-BFFD-365104DF487EQ41975992-9F6C4B90-F807-40B0-8597-644D714DD222Q42293865-22B3D07D-635F-432C-B3FA-5B3624EB49D9Q47112234-10449798-AED9-4EE9-8C5F-F1D22E8EE3BEQ47128924-BD584AA8-33FA-4DA1-B61C-530117E026F1Q48164363-DA914CEE-A349-4226-B520-AE55B658A84DQ48167667-5B8F23E7-AC19-4407-945C-B5F7E3C7B8E5Q48614497-32BFDEA3-1162-476E-81E8-0ACAB1EE38BCQ51047922-8E5481B3-E4E3-476E-8109-C5A194DDE4B0Q53410082-BE248B15-88C3-4DF4-B5E4-CC2E2BCF7263
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The serotonergic system in Parkinson's disease.
@en
The serotonergic system in Parkinson's disease.
@nl
type
label
The serotonergic system in Parkinson's disease.
@en
The serotonergic system in Parkinson's disease.
@nl
prefLabel
The serotonergic system in Parkinson's disease.
@en
The serotonergic system in Parkinson's disease.
@nl
P1476
The serotonergic system in Parkinson's disease.
@en
P2093
Philippe Huot
P304
P356
10.1016/J.PNEUROBIO.2011.08.004
P577
2011-08-22T00:00:00Z